Mr. Evan Levine reports

PSYBIO THERAPEUTICS BEGINS FILING GLOBAL PROVISIONAL PATENT CONVERSION APPLICATIONS TO FURTHER STRENGTHEN BIOSYNTHETIC PATENT PORTFOLIO

Psybio Therapeutics Corp. has submitted an application to convert existing provisional patents to full patents. This submission covers major markets including North America, Europe, Asia Pacific and Africa, as well as other important countries. This continued collaboration with Miami University is anticipated to expedite progress toward the filing of an investigational new drug (IND) application with the United States Food and Drug Administration (FDA).

"We remain focused on the development of psycho-targeted therapeutic candidates as one of the only biotechnology companies in the psychoactive therapeutic industry developing their own compounds," stated Evan Levine, Psybio's chief executive officer. "Intellectual property protection is crucial for our current and future investors and partners, and we continue to be committed to the ongoing development and submission of patent applications and conversions."

Psybio acquired the global, exclusive and perpetual rights to license the platform technology developed at Miami University in Oxford, Ohio, enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria. Continuing patent coverage extension such as this submission further extends and expands that intellectual property protection.

"Solidifying these provisional patents and protecting our intellectual property is vital for the development of Psybio, which is in the process of premanufacturing and production optimization," stated Michael Spigarelli, MD, PhD, MBA, Psybio's chief medical officer. "The submission of the additional data regarding the process and production of tryptamines and related compounds is an important step in our growth objectives."

About Psybio Therapeutics Corp.

Psybio Therapeutics is an integrated and intellectual-property-driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering, as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development are currently continuing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The company utilizes a bio-medicinal chemistry approach to therapeutic development in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogues, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

We seek Safe Harbor.